IDEXX Laboratories, Inc. $IDXX Shares Purchased by O Shaughnessy Asset Management LLC

O Shaughnessy Asset Management LLC raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 16.8% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 25,672 shares of the company’s stock after buying an additional 3,685 shares during the period. O Shaughnessy Asset Management LLC’s holdings in IDEXX Laboratories were worth $17,368,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in IDEXX Laboratories by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock valued at $6,364,638,000 after buying an additional 86,040 shares during the last quarter. Elyxium Wealth LLC acquired a new stake in IDEXX Laboratories during the 4th quarter valued at $3,666,459,000. Geode Capital Management LLC grew its holdings in IDEXX Laboratories by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock valued at $1,749,380,000 after buying an additional 86,263 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in IDEXX Laboratories by 63,503.9% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock valued at $977,210,000 after buying an additional 1,442,174 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of IDEXX Laboratories by 14.0% during the third quarter. Invesco Ltd. now owns 1,320,263 shares of the company’s stock worth $843,503,000 after purchasing an additional 161,782 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 3.2%

Shares of IDXX opened at $578.89 on Wednesday. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $45.66 billion, a P/E ratio of 42.63, a price-to-earnings-growth ratio of 3.07 and a beta of 1.55. The stock’s fifty day simple moving average is $563.22 and its 200 day simple moving average is $630.28. IDEXX Laboratories, Inc. has a twelve month low of $506.91 and a twelve month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period last year, the company posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on IDXX shares. Citigroup started coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Finally, UBS Group decreased their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Seven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.